Susquehanna International Group
NGM

Susquehanna International Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Susquehanna International Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,900
Closed -$52.6K – 13472
2023
Q1 		$52.6K Sell
12,900
-50,900
-80% -$235K ﹤0.01% 11681
2022
Q4 		$320K Sell
63,800
-35,500
-36% -$223K ﹤0.01% 8928
2022
Q3 		$1.3M Buy
99,300
+55,300
+126% +$837K ﹤0.01% 5957
2022
Q2 		$564K Buy
+44,000
New +$609K ﹤0.01% 7974
2021
Q4 		– Sell
-16,900
Closed -$355K – 14128
2021
Q3 		$355K Buy
+16,900
New +$372K ﹤0.01% 10217
2021
Q2 		– Sell
-25,900
Closed -$753K – 13442
2021
Q1 		$753K Buy
25,900
+14,500
+127% +$406K ﹤0.01% 8459
2020
Q4 		$345K Buy
+11,400
New +$249K ﹤0.01% 9000

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's NGM Position: Q1 2024 in Review

Susquehanna International Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 35,092 shares — an estimated $30.1K sold.

Susquehanna International Group first reported a position in NGM in Q1 2020 and held it in 11 quarters. The position peaked at $416K in Q4 2020. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Susquehanna International Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 35,092 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $30.1K.
  • Susquehanna International Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
  • Susquehanna International Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $416K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.